培美曲塞联合顺铂化疗对非小细胞肺癌患者血清肿瘤标志物的影响

Effect of Pemetrexed Combined with Cisplatin Chemotherapy on Serum Tumor Markers in Patients with Non-small Cell Lung Cancer

目的:评估培美曲塞联合顺铂化疗方案对非小细胞肺癌(NSCLC)患者肿瘤相关标志物水平的改变,为临床治疗提供更加精准和全面的指导。方法:选取2021年10月—2023年6月苏州永鼎医院、齐齐哈尔医学院附属第一医院和苏州京东方医院收治的80例NSCLC患者作为研究样本,通过随机数字表法将患者分为对照组(n=40)和观察组(n=40),对照组给予注射用紫杉醇(白蛋白结合型)联合顺铂化疗,观察组给予培美曲塞联合顺铂化疗。比较两组患者治疗前及治疗2个周期后血清肿瘤标志物、免疫功能及生活质量[肺癌治疗功能评价量表(functional assessment of cancer therapy-lung,FACT-L)]。结果:治疗2个周期后,两组患者的癌胚抗原(carcinoembryonic antigen,CEA)、神经元特异性烯醇化酶(neuron-specific enolase,NSE)、细胞角蛋白19片段(cytokeratin 19 fragment,Cyfra 21-1)、糖类抗原125(carbohydrate antigen 125,CA125)水平均较治疗前有所下降,且观察组均低于对照组(P<0.05);治疗2个周期后,两组患者的CD8^(+)水平均较治疗前上升,但观察组较对照组低,CD4^(+)、CD4^(+)/CD8^(+)水平均较治疗前下降,但观察组均较对照组高(P<0.05);治疗2个周期后观察组患者FACT-L各维度评分均高于对照组,差异均有统计学意义(P<0.05)。结论:培美曲塞联合顺铂化疗在NSCLC可以有效降低患者血清中的肿瘤标志物水平,同时改善患者的免疫功能,从而提升患者的生活质量。

Objective:To evaluate the changes of tumor-related markers in patients with non-small cell lung cancer(NSCLC)by Pemetrexed combined with Cisplatin chemotherapy regimen,and to provide more accurate and comprehensive guidance for clinical treatment.Method:A total of 80 NSCLC patients admitted to Suzhou Yongding Hospital,the First Affiliated Hospital of Qiqihar Medical College and Suzhou BOE Hospital from October 2021 to June 2023 were selected as study samples.Patients were divided into control group(n=40)and observation group(n=40)by random number table method.The control group was given Paclitaxel for Injection(Albumin Bound)combined with Cisplatin chemotherapy,and the observation group was given Pemetrexed combined with Cisplatin chemotherapy.Serum tumor markers,nutritional status,immune function and quality of life[functional assessment of cancer therapy-lung(FACT-L)]were compared between the two groups before treatment and after 2 cycles of treatment.Result:After 2 cycles of treatment,the levels of carcinoembryonic antigen(CEA),neuronespecific enolase(NSE),cytokeratin 19 fragment(Cyfra 21-1)and carbohydrate antigen 125(CA125)in both groups were decreased compared with before treatment,and the observation group were lower than those of the control group(P<0.05).After 2 cycles of treatment,CD8^(+)levels in both groups increased compared with before treatment,but which was lower in observation group compared with control group,CD4^(+)and CD4^(+)/CD8^(+)levels decreased compared with before treatment,but which was higher in observation group compared with control group(P<0.05).After 2 cycles of treatment,FACT-L scores in observation group were higher than those in control group,the differences were statistically significant(P<0.05).Conclusion:Pemetrexed combined with Cisplatin chemotherapy can effectively reduce the tumor markers in the serum of patients with NSCLC,and improve the immune function of patients,thus improving the quality of life of patients.